<SUBMISSION>
<ACCESSION-NUMBER>0000920148-00-000028
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>2
<PERIOD>20000606
<ITEMS>5
<ITEMS>7
<FILING-DATE>20000607
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>LABORATORY CORP OF AMERICA HOLDINGS
<CIK>0000920148
<ASSIGNED-SIC>8071
<IRS-NUMBER>133757370
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>001-11353
<FILM-NUMBER>650488
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>358 S MAIN ST
<CITY>BURLINGTON
<STATE>NC
<ZIP>27215
<PHONE>3362291127
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>358 S MAIN ST
<STREET2>4225 EXECUTIVE SQUARE, SUITE 800
<CITY>BURLINGTON
<STATE>NC
<ZIP>27215
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>NATIONAL HEALTH LABORATORIES HOLDINGS INC
<DATE-CHANGED>19940314
</FORMER-COMPANY>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>0001.txt
<TEXT>




      UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                   WASHINGTON, D.C. 20549

                          FORM 8-K

                       CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934
                        June 6, 2000
                     ------------------
              (Date of earliest event reported)


         LABORATORY CORPORATION OF AMERICA HOLDINGS
         ------------------------------------------
   (Exact name of registrant as specified in its charter)


   DELAWARE                1-11353             13-3757370
 --------------          -----------         --------------
(State or other         (Commission         (IRS Employer
jurisdiction of         File Number)         Identification
incorporation)                                    Number)


   358 SOUTH MAIN STREET, BURLINGTON, NORTH CAROLINA 27215
   -------------------------------------------------------
          (Address of principal executive offices)

                        336-229-1127
                        ------------
    (Registrant's telephone number, including area code)


<PAGE>

ITEM 5. OTHER EVENTS

  On  June  6,  2000,  Laboratory   Corporation  of  America-
Registered Trademark- Holdings (LabCorp-Registered Trademark-)
announced that it has called for redemption  on July  7, 2000
all of its outstanding  8 1/2 percent  Series   A Convertible
Exchangeable  Preferred  Stock  and  8 1/2  percent  Series B
Convertible Pay-in-Kind Preferred Stock.

  The  redemption price for both the Series A and  Series  B
preferred stock is $52.83 per preferred share.  The Series A
preferred  stock is currently, and following June 30,  2000,
the  Series  B  preferred will be, convertible into  LabCorp
common  stock  at  the  rate of 1.81818  common  shares  per
preferred  share at any time prior to 5:00  p.m.,  New  York
City time, on July 6, 2000.

  Also,  LabCorp  reported  that Roche  Holdings,  Inc.  has
indicated that it plans to sell up to 2.5 million shares  of
common  stock to a limited number of investors in order  not
to  become  a majority shareholder of LabCorp.  LabCorp  has
filed  a  registration  statement with  the  Securities  and
Exchange Commission relating to this offer and sale by Roche
of LabCorp stock, but the registration statement has not yet
become  effective.  Such securities may not be sold nor  may
offers to buy be accepted prior to the time the registration
becomes effective.

ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL
        INFORMATION AND EXHIBITS

 (c)  Exhibit
      20  Press release of the Company dated
          June 6, 2000.

<PAGE>

                         SIGNATURES

Pursuant to the requirements of the Securities and Exchange
Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly
authorized.

          LABORATORY CORPORATION OF AMERICA HOLDINGS
          ------------------------------------------
                         (Registrant)

               By: /s/BRADFORD T. SMITH
                  ------------------------------
                      Bradford T. Smith
                      Executive Vice President,
                      General Counsel, Secretary
                      and Compliance Officer



Date: June 7, 2000

<PAGE>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-20
<SEQUENCE>2
<FILENAME>0002.txt
<TEXT>


Laboratory Corporation of America-Registered Trademark- Holdings
358 South Main Street
Burlington, NC   27215
Telephone:  336-584-5171

FOR IMMEDIATE RELEASE

Contact:       336-436-4855             Shareholder Direct: 800-LAB-0401
               Pamela Sherry                                www.labcorp.com


      LABCORP ISSUES NOTICE OF REDEMPTION FOR PREFERRED STOCK

BURLINGTON, NC, JUNE 6, 2000 - Laboratory Corporation of America-
Registered Trademark- Holdings (LabCorp-Registered Trademark-)
(NYSE: LH) announced today that it has called for redemption on
July 7, 2000 all of its outstanding 8 1/2 percent Series A
Convertible Exchangeable Preferred Stock and 8 1/2 percent Series
B Convertible Pay-in-Kind Preferred Stock.

The redemption price for both the Series A and Series B preferred
stock is $52.83 per preferred share.  The Series A preferred
stock is currently, and following June 30, 2000, the Series B
preferred stock will be, convertible into LabCorp common stock at
the rate of 1.81818 common shares per preferred share at any time
prior to 5:00 p.m., New York City time, on July 6, 2000.  At such
time, assuming holders have not previously converted their
preferred stock and that LabCorp pays intervening dividends on
the Series B preferred stock in additional shares of Series B
preferred stock, there will be 4,229,175 and 7,283,445 shares of
Series A and Series B preferred stock, respectively, outstanding.
Conversion of all such shares of preferred stock into common
stock would result in the issuance of a total of 20,932,015
shares of common stock, which, together with the 13,341,038
common shares currently outstanding, would bring the total common
shares outstanding to 34,273,053.  Based on the closing price of
the common stock on the New York Stock Exchange on June 5 of
$66.875, each preferred share currently has a value of $121.59
(on an as-converted basis).  Holders may elect to convert
preferred stock in whole or in part, with cash to be paid in lieu
of fractional common shares.  LabCorp also stated that it intends
to declare dividends on the outstanding Series A and Series B
preferred stock through the redemption date and that its bank
syndicate has agreed to the amendment of its credit facility to
provide funding, if required, to the extent shares of Series A
preferred stock and any shares of Series B preferred stock held
by investors other than Roche Holdings, Inc. are not converted
prior to redemption.

<PAGE>
In the first quarter of 2000, LabCorp reported diluted earnings
per common share on a basis that reflected the conversion of all
shares of Series A and Series B preferred stock outstanding at
March 31, 2000 into common shares.

Also, LabCorp reported that Roche Holdings, Inc. has indicated
that it plans to sell up to 2.5 million shares of common stock to
a limited number of investors in order not to become a majority
shareholder of LabCorp.

Roche currently owns approximately 6,133,000 or 46 percent of
LabCorp common shares and Series B preferred stock
convertible into approximately 11,720,000 LabCorp common
shares.  At June 30, 2000, assuming Roche sells the full
amount of the 2.5 million shares of common stock and all
of the Series A and Series B preferred stock (including
the Series B preferred stock held by Roche) is converted,
Roche's ownership of LabCorp common stock would be
approximately 45 percent.

LabCorp has filed a registration statement with the Securities
and Exchange Commission relating to this offer and sale by
Roche of LabCorp stock, but the registration statement has
not yet become effective.  Such securities may not be sold
nor may offers to buy be accepted prior to the time the
registration statement becomes effective.

FORWARD-LOOKING CAUTIONARY STATEMENT: This release contains
statements that constitute forward-looking information.
Such statements are subject to certain risks,
uncertainties and assumptions.  All of these forward-
looking statements are based on estimates and assumptions
made by LabCorp's management which, although believed by
LabCorp's management to be reasonable, are inherently
uncertain.  Such forward-looking statements are not
guarantees of future performance or results and involve
certain risks and uncertainties.  Actual results or
developments may differ materially from these forward-
looking statements as a result of various factors. Further
information on potential factors that could affect
LabCorp's financial results is included in the Company's
Form 10-K for the year ended December 31, 1999 and
subsequent SEC filings.

</TEXT>
</DOCUMENT>
</SUBMISSION>
